跳至主要内容
临床试验/ACTRN12617000960358
ACTRN12617000960358招募中未知

PGX® supplementation to improve satiety, glucose, HbA1c, lipid status and weight loss in overweight and obese children.

Curtin University0 个研究点目标入组 70 人开始时间: 2017年7月4日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
9 Years 至 13 Years(—)
性别
All

入选标准

  • Overweight and obese children with a body mass index (BMI) above the 85th percentile of growth charts (WHO BMI for age percentile, approx. BMI 25-35) for age and sex, who are aged between 9-13 years.

排除标准

  • Exclusion criteria will include medications and conditions that influence appetite or metabolism, use of steroids and other agents or medications that may influence lipid metabolism, use of warfarin, diabetes, hypo- and hyperthyroidism, cardiovascular events within in the last 6 months, psychological unsuitability, major systemic diseases, gastrointestinal problems (including difficulty swallowing), dairy allergies (eg. lactose intolerance), proteinuria, liver or renal failure, vegetarianism, passive smoking, substance abuse, and use of fibre supplements.

研究者

相似试验